Clinical Trials Browser

Unknown × tislelizumab × Tumor-Agnostic × Clear all

NCT04985721 2023-03-15

IMPARP-HRD

Phase 2 Unknown

Neoplasms

NCT05241132 2022-02-15

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Phase 2 Unknown

Neoplasms